South China(Foshan) April 21 RMB/T,1ton≈2204.62lbs -2800 copper cathode(domestic standard) 38100-38300 -2800 oxygen free rod 8mm -2800 low-oxygen copper rod 8mm -2800 copper wire (1.13-2.52mm) -2800 copper wire2.6mm -2800 H65copper strap(0.3-0.8mm,y2) -2700 H62copper strap(0.18-0.25mm.y.y2) -2800 rod brass(14mm-120mm) -2800 clean copper clippings -2800 high grad
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Yritti äskettäin viagra, se toimii erittäin tehokkaasti)) Ostaa Internetin kautta täällä viagra Myös ostaa levitra oikeudenkäynti, vaikutus on silmiinpistävää.
Survey on cannabis use in parkinson's disease: subjective improvement of motor symptoms5. Powers JM. Blepharospasm due to unilateral diencephalon infarc- 6. Keane JR, Young JA. Blepharospasm with bilateral basal ganglia infarction. Arch Neurol 1985;42:1206 –1208.
7. Verghese J, Rosenbaum DM. Ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage. Neurology1999;53:652.
8. Schmidtke K, Butnner-Ennever JA. Nervous control of eyelid function: a review of clinical, experimental and pathological data.
9. Hallet M. Blepharospasm. Recent advances. Neurology 2002;59: 10. Wali GM. Asymmetrical blepharospasm associated with a left frontal cortical infarct. Mov Disord 2001;16:181–182.
11. Perlmutter JS, Stambuk MK, Markham J, et al. Decreased 18F- spiperone binding in putamen in idiopathic focal dystonia. J Neu-rosci 1997;17:843– 850.
12. Esmaeli-Gutsein B, Nahmias C, Thompson M, et al. Positron emission tomography in patients with benign essential blepharo-spasm. Ophthalmol Plast Reconstr Surg 1999;15:23–27.
13. Schmidt K, Linden DE, Goebel R, Zamella F, Lanfermann H, Zubcov A. Striatal activation during blepharospasm revealed byfMRI. Neurology 2003;60:1738 –1743.
Survey on Cannabis Use in Parkinson’s
Disease: Subjective Improvement of
Evzˇen Ru˚zˇicˇka, MD, DSc,2* Viktor Vorˇı´sˇek, PharmD,3 FIG. 2. Brain magnetic resonance T2-weighted axial image showing a
right striatal infarct involving caudate and putamen.
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Hradec Kra´love´, The eyelid motor disturbance in our patient was transient, with complete remission in 2 weeks. This ﬁnding may be related to the 2Movement Disorders Centre, Department of Neurology, 1st recovery of normal function that often occurs after ischemia, Medical Faculty, Charles University, Prague, Czech Republic although some compensatory mechanisms also might have taken 3Division of Clinical Toxicology and Mass Spectrometry, place during this time. For instance, in addition to an improvement Department of Biochemistry, University Hospital Hradec of a possible edema of the internal capsule, the intact hemisphere could have taken over or even a functional reorganization of theipsilateral cerebral cortex could have occurred.
Abstract: An anonymous questionnaire sent to all patients
In conclusion, unilateral striatal infarctions may cause a attending the Prague Movement Disorder Centre revealed that transient prominent reﬂex blepharospasm. These eyelid abnor- 25% of 339 respondents had taken cannabis and 45.9% of these malities may reﬂect a disruption of a common supranuclear described some form of beneﬁt. 2004 Movement Disorder pathway linking the nondominant cerebral hemisphere, the basal ganglia, and the brainstem, and emphasize the role of the Key words: cannabis; Parkinson’s disease; cannabinoid
striatum, particularly the putamen, in the pathophysiology ofsome eyelid motor disorders.
The cannabis plant (Cannabis sativa) contains compounds References
called cannabinoids that are exclusive to the Cannabaceaefamily. These compounds exert their pharmacologic effect by 1. Hijosa M, Esteban A, Sanchez Migallon MJ, Grandas F. Palpebral acting on speciﬁc G protein-coupled cannabinoid receptors.
ptosis and blepharospasm secondary to hemispheric cerebral in-farction. Neurologia 1998;13:49 –53.
2. Averbuch-Heller L, Leigh RJ, Mermelstein V, Zagalski L, Streiﬂer JY. Ptosis in patients with hemispheric strokes. Neurology 2002; *Correspondence to: Dr. Evzˇen Ru˚zˇicˇka, Movement Disorders Cen- tre, Department of Neurology, 1st Medical Faculty, Charles University, 3. Lee MS, Marsden CD. Movement disorders following lesions of the Prague, Czech Republic. E-mail: firstname.lastname@example.org thalamus and subthalamic region. Mov Disord 1994;9:493–507.
Received 12 July 2003; Revised 20 December 2003; Accepted 16 4. Larumbe R, Vaamonde J, Artieda J, et al. Reﬂex blepharospasm associated with bilateral basal ganglia lesion. Mov Disord 1993; Published online 21 April 2004 in Wiley InterScience (www.
interscience.wiley.com). DOI: 10.1002/mds.20111
Movement Disorders, Vol. 19, No. 9, 2004 TABLE 1. Mean age and duration of Parkinson’s disease in
uses cannabis, how frequently, how regularly, for how long, patients who had used and not used cannabis which part of the plant, whether there was an effect on cardinal motor symptoms of PD and on levodopa (L-dopa)-induceddyskinesias, and if any, when the effect had appeared), on the possible use of other drugs of abuse and current antiparkinso- nian treatment. The terms muscle rigidity, bradykinesia, and dyskinesias were explained brieﬂy. Patients were asked to rate the subjective changes in each symptom and dyskinesias asfollows: substantial improvement, mild improvement, nochange, mild worsening, substantial worsening, or I do notknow. We have analyzed urine from 7 patients who had taken Two types of cannabinoid receptors have been isolated so far.
cannabis regularly for more than one year and a single patient CB receptor is localized predominantly in the central nervous who had only taken it 1 day before analysis. The patients had system (CNS),1 whereas CB is found mostly in organs and expressed their willingness to participate in further studies, had cells of the immune system. To date, a number of endogenous reported cannabis use, and were able to attend the hospital to agonists at cannabinoid receptors have been isolated that in- submit urine samples. We carried out preliminary screening clude anandamide2 and 2-arachidonyl glycerol (2-AG).3 (EMIT II plus Cannabinoid Assay; Dade Behring, USA) fol- The potential use of cannabis or cannabinoids in pharmaco- lowed by gas chromatography/mass spectrometry (GC/MS) therapy of various medical conditions including Parkinson’s quantitative analysis (ion 371 m/z was monitored in silylated disease (PD) and dyskinetic movement disorders has been 11-nor-␦-9-tetrahydrocannabinol-9-carboxylic acid; 11-nor-␦- discussed recently,4 substantiated by rich representation of can- 9-THCOOH) on ion trap spectrometer Magnum (ThermoFinni- nabinoid system in the basal ganglia. The globus pallidus and gan) equipped with capillary column DB1ms (30 m; 0.25 m; substantia nigra pars reticulata contain the highest density of 0.25 mm; JW Scientiﬁc-Agilent, USA; silylation reagent: bis(tri- CB receptors in the body.5,6 The concentration of anandamide methylsilyl)triﬂuoroacetamide) ϩ trimethylchlorosilane 99:1; in the globus pallidus and substantia nigra is three times higher standards: drugs of abuse control S1, S2 and S3 (Bio-Rad)). For than in other brain regions.7 Cannabinoid system therefore extraction of cannabinoids, SPEC-C18-I Cartridges (Ansys, might play some physiological role in the basal ganglia control Inc., USA) and vacuum extractor Supelco Visiprep 24 were of movement and this is supported by the ﬁnding that CB1 knockout mice exert lower locomotor activity.8,9 The use of cannabis has been presented in Czech media as being possibly helpful in Parkinson’s disease, which was ini-tiated mainly by one of our patients who objectively improved Out of 630 questionnaires sent by mail, 339 (53.8%) were his PD symptoms after long-term use of cannabis.10 We real- returned (195 men, 139 women; 5 without answer regarding ized that after this public information, some of our patients gender). The responders’ mean age was 65.7 years (age range, spontaneously started to take cannabis to alleviate their PD 36 –92 years) and the mean PD duration was 8.5 years (range, symptoms. The aim of this study therefore is to evaluate their Ͻ1–30 years). Cannabis use was reported by 85 patients (25.1% of returned questionnaires; 55 men, 29 women, 1 with-out answer), most of them using approximately half a teaspoonof fresh or dried leaves orally (only 1 patient inhaled), usually Subjects and Methods
with meals (43.5%) and mostly once a day (52.9%). There were The protocol was approved by the Research Ethics Commit- no major differences in age and duration of PD between the tee of the General University Hospital in Prague and informed subgroup of patients using cannabis and those who had never consent was obtained from all subjects participating in the used it (Table 1). Patients mostly decided to take cannabis analytical part of this study. All patients with PD registered at based on information presented in the media. None of the Prague Movement Disorders Centre were asked to anony- patients had any experience with recreational use of cannabis mously complete a questionnaire about their possible experi- before taking it to alleviate PD symptoms. None had been ence with cannabis. For this purpose, we modiﬁed the ques- advised to use cannabis by a doctor, and all patients continued tionnaire that Consroe and colleagues11 used to describe the using the antiparkinsonian therapy recommended by their neu- effects of cannabis on multiple sclerosis symptoms. This ques- rologist. After cannabis, 39 patients (45.9%) described mild or tionnaire asks for basic personal data (age, gender, duration of substantial alleviation of their PD symptoms in general, 26 PD), questions on the possible use of cannabis (if the patient (30.6%) improvement of rest tremor, 38 (44.7%) alleviation of TABLE 2. Relationship between the duration of cannabis use and number of patients reporting alleviation of symptoms
cannabis use Total (n) Improved improved answer Improved improved answer Improved improved answer Improved improved answer Movement Disorders, Vol. 19, No. 9, 2004 TABLE 3. Relationship between the frequency of cannabis
bradykinesia or rigidity. In contrast, in patients where 11-nor- doses and number of patients reporting improvement ␦-9-THCOOH levels were lower than 50 ng/ml (3/7), there was no reported improvement in either. It is of interest that 1 patientwho did not take cannabis regularly but who had taken it the day before analysis had higher urine levels of 11-nor-␦-9-THCOOH (132.2 ng/ml), but reported no improvement in symptoms, a ﬁnding consistent with the conclusions of the questionnaire, which were that chronic use of cannabis might be required to obtain a subjective improvement in symptoms.
bradykinesia, 32 (37.7%) alleviation of muscle rigidity, and 12 Possible involvement of the cannabinoid system in PD (14.1%) improvement of L-dopa-induced dyskinesias (Table 2 pathophysiology was shown in several experimental animal and 3). Only 4 patients (4.7%) reported that cannabis actually models of PD7,12–14 and in one postmortem study.15 Potential use of cannabinoids in PD is controversial. Some authors According to the information obtained from the patients, this suggest that CB receptor antagonists could prove useful in the alleviation occurred 1.7 months in average (range, 1 hour to 6 treatment of parkinsonian symptoms and L-dopa-induced dys- months) after their ﬁrst cannabis use. Patients using cannabis kinesia,16–18 whereas CB receptor agonists could have value in for at least 3 months reported signiﬁcantly more often a mild or reducing L-dopa-induced dyskinesia,16,18,19 which was also substantial alleviation of their PD symptoms in general (P Ͻ demonstrated in a recent clinical study.20 In an earlier clinic 0.001, 2 test), improvement of resting tremor (P Ͻ 0.01, 2 report, however, no effects of smoked cannabis were observed test), bradykinesia (P Ͻ 0.01, 2 test), and muscle rigidity (P Ͻ 0.01, 2 test) (Table 2). Although there was no relationship The aim of our study was to evaluate the frequency and between the length of cannabis use and the effect on dyskinesia, patterns of cannabis use in PD patients, focusing especially on patients using cannabis on a regular basis at least once a day possible subjective changes in cardinal motor symptoms and reported an improvement in their dyskinesias signiﬁcantly L-dopa-induced dyskinesias. The results obtained from the more frequently than did those who were taking cannabis less questionnaires show that bradykinesia seems to be the symp- than once a day (Table 3, P Ͻ 0.05, 2 test). We did not ﬁnd tom most commonly improved by cannabinoids, followed by any inﬂuence of patients’ age (2 test), duration of PD (2 test), muscle rigidity and tremor. In addition, 14% of our patients part of the plant used (Kruskal-Wallis test) or whether fresh or reported alleviation of dopaminergic-induced dyskinesias with cannabis use. Unfortunately, we do not know how many pa- Only 2 patients used cannabis for purposes other than alle- tients in the anonymous study actually suffered from dyskine- viation of PD symptoms: 1 patient used cannabis “to relieve sias. In fact, many PD patients are not aware of dyskinesias and depression” and 1 “to have more energy.” None of the respon- thus cannot evaluate accurately any possible antidyskinetic dents ever used cannabis to experience hallucinations, to re- lieve anxiety, or to relax; however, the questionnaire did not The late onset of cannabis action is noteworthy. Because ask directly if they had experienced any psychoactive effects most patients reported that improvement occurred approxi- when using cannabis. Three patients reported that they had mately 2 months after the ﬁrst use of cannabis, it is very discontinued using cannabis because of unspeciﬁed side ef- unlikely that it could be attributed to a placebo reaction. The results from the analytical part of the study (GC/MS) also In the group of 7 patients who were using cannabis consis- support our observation that long-term regular use of cannabi- tently over several months, an effect of urine level of 11-nor- noids is crucial. Possible explanations include gradual accumu- ␦-9-THCOOH (major ␦-9-THC metabolite in the urine) on lation of low doses of highly lipophilic ␦-9-THC before reach- bradykinesia and rigidity was apparent. In all patients in which ing higher concentrations necessary for stimulation of urine levels (Table 4) of 11-nor-␦-9-THCOOH were higher movement,22 or regulations on the level of CB receptors.23–26 than 50 ng/ml (4/7), there was a reported improvement in This observation is in contrast with the study of Sieradzan and TABLE 4. Relationship between the concentration of 11-nor-␦-9-THCOOH in urine and change of symptoms in a subset of PD
patients with long-term cannabis use Movement Disorders, Vol. 19, No. 9, 2004 colleagues,20 where the action of synthetic cannabinoid agonist 8. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner occurred within minutes or hours after administration. The TI. Increased mortality, hypoactivity, and hypoalgesia in cannabi- design of these two studies, however, including the doses used, noid CB1 receptor knockout mice. Proc Natl Acad Sci USA was very different. Although in regular users the subjective 9. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A. Altered improvement of symptoms seemed to correlate well with con- gene expression in striatal projection neurons in CB1 cannabinoid centrations of the major metabolite of ␦-9-THC found in urine, receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5786 – the actions of other plant cannabinoids have to be considered because they may substantially inﬂuence the effect of ␦-9-THC 10. Ru˚zˇicˇka E. Chewing marijuana induced improvement in Parkin- alone.27,28 The most likely is cannabidiol, which inhibits uptake son’s disease. Parkinsonism Relat Disord 1999;5:85 and hydrolysis of anandamide and acts as a vanilloid receptor 11. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. Perceived (VR ) agonist.29 Cannabinoids may also have a protective role in effects of cannabis smoking on patients with multiple sclerosis.
slowing down progression of a neurodegenerative process.30–32 The present study evaluating spontaneous use of natural 12. Gubellini P, Picconi B, Bari M, et al. Experimental parkinsonism cannabis in PD patients suggests that cannabis may improve alters endocannabinoid degradation: implications for striatal glu-tamatergic transmission. J Neurosci 2002;22:6900 – 6907.
PD symptoms and L-dopa-induced dyskinesias. Due to the 13. Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie illegal status of cannabis in the Czech Republic, it was impos- JM. Striatal cannabinoid CB1 receptor mRNA expression is de- sible to run a proper clinical trial and we had to use an creased in the reserpine-treated rat model of Parkinson’s disease.
anonymous retrospective questionnaire-based study; we are well aware of its limitations. Questionnaires are used quite 14. Romero J, Berrendero F, et al. Unilateral 6-hydroxydopamine commonly in clinical research because they enable obtaining lesions of nigrostriatal dopaminergic neurons increased CB1 re- data from a large group of patients; however, results from this ceptor mRNA levels in the caudate-putamen. Life Sci 1999;66: type of study cannot be conclusive and should rather serve as a baseline for future research. Even though a possible placebo 15. Lastres-Becker I, Cebeira M, de Ceballos ML, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding reaction and other confounders (e.g., concomitant antiparkin- proteins in the basal ganglia of patients with Parkinson’s syndrome sonian therapy, non-standardized plant material) have to be and of MPTP-treated marmosets. Eur J Neurosci 2001;14:1827– taken into account, it seems that various cannabinoids or other compounds targeting the endogenous cannabinoid system 16. Brotchie JM. CB(1) cannabinoid receptor signalling in Parkinson’s might be useful in the treatment of PD symptoms or drug- disease. Curr Opin Pharmacol 2003;3:54 – 61.
induced dyskinesias and this ﬁeld deﬁnitely deserves further 17. Brotchie JM, Fox SH, Henry B, et al. The cannabinoid receptor antagonist SR 141716A reduces L-dopa-induced dyskinesia in theMPTP-treated primate model of Parkinson’s disease. Br J Phar- Acknowledgments: This study was supported by the Czech Minis-
try of Education (CEZ:J13/98:11600004 and 11100001). We thank L.
18. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic Jahoda´rˇ (Faculty of Pharmacy, Charles University, Hradec Kra´love´) for approach to reducing the problem of dyskinesia in Parkinson’s advice and support, P. Klemera (Faculty of Pharmacy, Charles Univer- disease. Mov Disord 1998;13:871– 876.
sity, Hradec Kra´love´) for help with statistical analysis, J. Roth, P.
19. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of Mecˇı´rˇ, R. Jech, and M. Volfova´ for their clinical followup of patients cannabinoid receptors reduces levodopa-induced dyskinesia in the in the Movement Disorders Centre, Prague, and P. Consroe (University MPTP-lesioned nonhuman primate model of Parkinson’s disease.
of Arizona Health Sciences Center, Tucson, AZ) for kindly providing 20. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkin- References
son’s disease: a pilot study. Neurology 2001;57:2108 –2111.
21. Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for parkin- 1. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor sonian tremor. J Neurol Neurosurg Psychiatry 1990;53:436.
mediated regulation of gastrointestinal motility in mice in a model 22. Sanudo-Pena MC, Romero J, Seale GE, Fernandez-Ruiz JJ, of intestinal inﬂammation. Br J Pharmacol 2001;134:563–570.
Walker JM. Activational role of cannabinoids on movement. Eur 2. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel en- 23. Zhuang S, Kittler J, Grigorenko EV, et al. Effects of long-term dogenous cannabimimetic metabolite 2-arachidonoyl glycerol in exposure to ␦9-THC on expression of cannabinoid receptor (CB1) mouse neuroblastoma cells. Biochem J 1997;322:671– 677.
mRNA in different rat brain regions. Brain Res Mol Brain Res 3. Fride E, Mechoulam R. Pharmacological activity of the cannabi- noid receptor agonist, anandamide, a brain constituent. Eur J Phar- 24. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA.
Changes in rat brain cannabinoid binding sites after acute or chronic 4. Muller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in exposure to their endogenous agonist, anandamide, or to ␦-9-tetrhy- movement disorders. Forsch Komplementarmed 1999;3(Suppl.): drocannabinol. Pharmacol Biochem Behav 1995;51:731–737.
25. Rubino T, Vigano D, Massi P, et al. Chronic ␦-9-tetrahydrocan- 5. Sanudo-Pena MC, Tsou KJ, Walker JM. Motor actions of canna- nabinol treatment increases cAMP levels and cAMP dependent binoids in the basal ganglia output nuclei. Life Sci 1999;65:703– protein kinase activity in some rat brain regions. Neuropharmacol- 6. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM.
26. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of Immunohistochemical distribution of cannabinoid CB1 receptor in chronic treatment with ␦9-tetrhydrocannabinol on cannabinoid- the rat central nervous system. Neuroscience 1998;83:393– 411.
stimulated [35S]GTPgammaS autoradiography in rat brain. J Neu- 7. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM.
Enhanced levels of endogenous cannabinoids in the globus palli- 27. Formukong EA, Evans AT, Evans FJ. Inhibition of the cataleptic dus are associated with a reduction in movement in an animal effect of tetrahydrocannabinol by other constituents of Cannabis model of Parkinson’s disease. FASEB J 2000;14:1432–1438.
sativa L. J Pharm Pharmacol 1988;40:132–134.
Movement Disorders, Vol. 19, No. 9, 2004 28. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of The supplementary motor area (SMA) corresponds to the cannabidiol pretreatment on the kinetics of tetrahydrocannabinol medial aspect of Brodmann area 6 on the medial wall of the metabolites in mouse brain. Drug Metab Dispos 1995;23:825– 831.
frontal lobe, which is essentially related to the initiation and 29. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for execution of the movement.16,17 It has been shown that SMA cannabidiol and its synthetic analogues: effect on vanilloid VR1 lesions cause various abnormalities of speech and motor func- receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845– 852.
We recently observed a patient who developed both acquired 30. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and stuttering and long-lasting gait disturbance after apparent SMA (Ϫ)␦-9-tetrahydrocannabinol are neuroprotective antioxidants.
seizure. His stuttering and gait disturbance gradually improved Proc Natl Acad Sci U S A 1998;95:8268 – 8273.
and almost completely resolved over 1 month.
31. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8: Case Report
32. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and A 37-year-old, right-handed man was admitted because of elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neu- speech and gait disturbances. He had been in good health until 28 months earlier, when he had a left anterior cerebral arteryterritorial infarction involving the left SMA and cingulate gyrus(Fig. 1A–C). At that time, he had experienced speech arrest andweakness of his right leg, which resolved over 10 days. Theetiology of the stroke was not determined, and he was dis- Stuttering and Gait Disturbance After
charged from the hospital on aspirin.
Supplementary Motor Area Seizure
Eighteen months after the stroke, he had what was consid- ered a left SMA seizure, which consisted of sudden speech Sun J. Chung, MD, Joo-Hyuk Im, MD,* Jae-Hong Lee, MD, arrest, head deviation to the right, tonic posturing of the right leg, and preserved consciousness. After the seizure, he haddifﬁculty with speech and walking that resolved gradually over Department of Neurology, University of Ulsan, Asan Medical 15 days. Subsequently, he was referred to our hospital for He denied any speech problems when he was a child. There was no history of cardiac disease, hypertension, diabetes, ortrauma. He had no family history of stuttering. On neurologic Abstract: Acquired stuttering is an uncommon speech disor-
examination, the cranial nerves, speech, motor power, and der. Supplementary motor area (SMA) lesions have been re- sensation were normal. On awakening 3 days after hospital ported to be directly or indirectly related to acquired stuttering admission, he was unable to walk alone; postural stability was and various types of motor dysfunction. We report on a patient markedly impaired with generalized paucity of body move- who presented with both acquired stuttering and long-lasting ment. Motor strength was normal. He was barely able to make gait disturbance after SMA seizure. 2004 Movement Dis- steps and only with assistance. His gait improved gradually and normalized over 20 days. During this episode, he showed nospeech disturbance. An electroencephalogram (EEG), brain Key words: supplementary motor area; stuttering; gait dis-
magnetic resonance angiogram (MRA), transcranial Doppler, and echocardiogram were all normal. Although the exact eti-ology of his gait disturbance was not found, it was clinically Stuttering has been deﬁned as a disruption in the ﬂuency of suspected that this episode was a postictal manifestation of an verbal expression, which is characterized by involuntary repe- SMA seizure. The patient was placed on valproic acid and titions or prolongations in the utterance of short speech ele- aspirin and did well without recurrent seizures or any other ments—namely, sounds, syllables, and words of one syllable.1 Developmental stuttering typically begins in childhood or early On the day of his second admission, he developed sudden adolescence.2,3 The etiology of developmental stuttering re- speech and gait disturbances after the SMA seizure thatlasted for approximately 5 minutes. On examination, he mains elusive. New stuttering in adulthood, or acquired stut- showed severe stuttering with an abnormal protruding move- tering, has been reported in a variety of diseases, including ment of his lips when he tried to speak (see video Segment strokes,4–12 Parkinson’s disease,13,14 progressive supranuclear 1). The stuttering did not improve with repetitive practice. It palsy,14 Alzheimer’s disease,15 and trauma.6,12,15 was similar in severity on both spontaneous speech and withrepetition. The stuttering was accompanied by severe slow-ness of orolingual and velopharyngeal movement. The dys- This article contains supplementary video clips, available at http:// ﬂuency of his speech was noted through entire sentences, but www.interscience.wiley.com/jpages/0885-3185/suppmat.
mainly at the beginning of words, phrases, or sentences.
*Correspondence to: Dr. Joo-Hyuk Im, Department of Neurology, When he read a book aloud, the severity of the stuttering Asan Medical Center, 388-1, Poongnap-dong, Songpa-gu, Seoul, South diminished and speech was monotonous. The speech distur- bance was also noted when he sang a familiar song. We also Received 7 April 2003; Revised 19 September 2003; Accepted 10 detected severe bilateral body bradykinesia and gait distur- Published online 22 April 2004 in Wiley InterScience (www.
bance. The bradykinesia was initially generalized but later interscience.wiley.com). DOI: 10.1002/mds.20136
was noted mainly in the lower extremities. He was initially Movement Disorders, Vol. 19, No. 9, 2004
Anaphylaxis 1. True or False: All patients with anaphylaxis will have respiratory symptoms. 2. Which medicine should be given first to a patient who is actively experiencing anaphylaxis? a. Prednisone PO b. Normal saline bolus IV c. Epinephrine IM d. Diphenhydramine IV/PO 3. Which preparation/administration of epinephrine is correct for a patient experiencing anaphylaxis? a.